US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Onestream Inc

27.51

-0.6300-2.24%

Volume:1.34M

Turnover:36.88M

Market Cap:4.85B

PE:-15.57

High:28.11

Open:27.84

Low:27.16

Close:28.14

Loading ...

Overview Company News Filings

Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma

Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings

Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

OS Therapies to Attend The Jones Healthcare and Technology Innovation Conference

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Press Release: SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

OneStream Initiated at Overweight by Stephens & Co.

Onestream, Inc. Class A (OS) Has a New Rating from Stephens

OneStream initiated with an Overweight at Stephens

Press Release: OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

QNX Announces Free Online Training Courses to Grow and Empower Global Developer Community

ACCESS Newswire

Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia

INAB: Introducing INB-600, A γδ T Cell Engager Platform

Zacks Small Cap Research

ELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients

OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference

OS Therapies Schedules United Kingdom’s Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma

QNX Extends Collaboration with AMD to Boost Performance in Robotic Systems

ACCESS Newswire

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/OS/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OS\",,,,,undefined,":{"symbol":"OS","market":"US","secType":"STK","nameCN":"Onestream Inc","latestPrice":27.51,"timestamp":1749844800000,"preClose":28.14,"halted":0,"volume":1338419,"delay":0,"floatShares":69821187,"shares":176260091,"eps":-1.766751,"marketStatus":"Pre-Mkt","change":-0.63,"latestTime":"06-16 07:01:12 EDT","open":27.84,"high":28.11,"low":27.162,"amount":36877108.041222,"amplitude":0.033689,"askPrice":31.09,"askSize":100,"bidPrice":25.04,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.766751,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1750080600000},"marketStatusCode":1,"adr":0,"listingDate":1721793600000,"exchange":"NASDAQ","adjPreClose":27.51,"postHourTrading":{"tag":"盘后","latestPrice":27.45,"preClose":27.51,"latestTime":"19:35 EDT","volume":30730,"amount":843754.23,"timestamp":1749857751404},"volumeRatio":1.099095181229347,"impliedVol":0.526,"impliedVolPercentile":0.3727},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OS\",,,,,undefined,":{"symbol":"OS","floatShares":69821187,"roa":"-35.83%","roe":"-108.78%","lyrEps":-1.232998,"volumeRatio":1.099095181229347,"shares":176260091,"dividePrice":0,"high":28.11,"amplitude":0.033689,"preClose":28.14,"low":27.162,"week52Low":16.6942,"pbRate":"11.74","psRate":"9.41","week52High":35.39,"institutionHeld":0,"latestPrice":27.51,"eps":-1.766751,"divideRate":0,"volume":1338419,"delay":0,"ttmEps":-1.766751,"open":27.84,"prevYearClose":28.52,"prevWeekClose":27.51,"prevMonthClose":28.06,"prevQuarterClose":21.34,"fiveDayClose":28.92,"twentyDayClose":28.35,"sixtyDayClose":22.17},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OS\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522875506","title":"Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2522875506","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522875506?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:16","pubTimestamp":1742987760,"startTime":"0","endTime":"0","summary":"Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in Glioblastoma, supporting further investigation of VXM01. The VXM01-avelumab combination therapy was generally well-tolerated, with the majority of safety events being mild to moderate in severity. These safety and tolerability data are in-line with previously reported data onavelumab alone with no additional safety signals for the combination of VXM01 and avelumab.No serious adverse events were attributed to VXM01, while9 of 11  were related to the target disease, underscoring the well manageable safety profile of this combination therapy in a frail patient population.The reported safety and tolerability data, together with early indications for the potential relevance of a VXM01dependent, VEGFR-2 specific immune response in GBM therapy warrant further study.\"The completion of this Phase 2a study is a significant mi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/vaximm-ag-osr-company-announces-111600323.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vaximm-ag-osr-company-announces-111600323.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AG","ORR","OS","BK4097","OSRHW","OSRH","BK4210","BK4139"],"gpt_icon":0},{"id":"2522187556","title":"Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2522187556","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522187556?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:05","pubTimestamp":1742987100,"startTime":"0","endTime":"0","summary":"Leap to host a conference call to present updated CRC clinical data today, March 26, 2025, at 8:00 a.m. ET. CAMBRIDGE, Mass., March 26, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. , a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024.Reported positive updated data from Part B of the Phase 2 DeFianCe study of sirexatamab  in second-line patients with advanced microsatellite stable  colorectal cancer  confirming:. Statistically significant 22% higherORR and 2.6 month longer PFS in patients who had not had prior anti-VEGF therapy. FL-501 abstract accepted for poster presentation at the 2025 American Association for Cancer Research  Annual Meeting.Across the intent-to-treat population, thesirexatamab Experimental Arm had improved ORR compared to the Control Arm, with PFS and OS maturing with a higher number of patients continuing to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/leap-therapeutics-reports-fourth-quarter-110500189.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/leap-therapeutics-reports-fourth-quarter-110500189.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BMPRXQ63.HKD","LU0348723411.USD","BK4585","LENZ","PFS","OS","MSS","BK4139","BK4563","BK4609","IE00BMPRXN33.USD","BK4141","BK4195","LU0456854461.SGD","ORR","BK4113","BK4588","CRC","BK4097","BK4505","BK4543","BK4211","BK4213","LPTX","IE00BMPRXR70.SGD","LU0266512127.USD"],"gpt_icon":1},{"id":"2522596875","title":"Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2522596875","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522596875?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:00","pubTimestamp":1742986800,"startTime":"0","endTime":"0","summary":"Updated data confirms statistically significant 32% higher ORR and 3.5 month longer PFSin second-line CRC patients with high DKK1 levels treated with sirexatamab plus bevacizumab and chemotherapy. Statistically significant 22% higher ORR and 2.6 month longer PFSin patients who had not had prioranti-VEGF therapy. Leap to host a conference call to present clinical data today, March 26, 2025, at 8:00 a.m. ET. \"The updated data from Part B of the DeFianCe study presented today confirms that sirexatamab can generate significantly higher ORR and longer PFS in CRC patients who have high levels of DKK1 or who have not had prior anti-VEGF therapy, two exploratory populations with strong scientific rationale. In the full intent-to-treat population, sirexatamab demonstrated a higher ORR and a tail population with longer PFS that continues to mature. With more sirexatamab-treated patients currently continuing on study drug than control arm patients, there is potential for the dataset to continue t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/leap-therapeutics-reports-positive-updated-110000183.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/leap-therapeutics-reports-positive-updated-110000183.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","IE00BMPRXR70.SGD","BK4563","LENZ","BK4585","BK4113","IE00BMPRXN33.USD","ARM","OS","BK4211","BK4141","LU0456854461.SGD","LU0348723411.USD","MSS","CRC","BK4609","BK4195","BK4505","LPTX","BK4543","IE00BMPRXQ63.HKD","BK4213","PFS","BK4097","LU0266512127.USD","BK4588","ORR"],"gpt_icon":0},{"id":"2522837332","title":"New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings","url":"https://stock-news.laohu8.com/highlight/detail?id=2522837332","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522837332?lang=en_us&edition=fundamental","pubTime":"2025-03-26 07:02","pubTimestamp":1742943720,"startTime":"0","endTime":"0","summary":"SAVANNAH and ORCHARD Phase II trials show the addition of savolitinib or datopotamab deruxtecan-dlnk to TAGRISSO upon disease progression demonstrates strong clinical activity. WILMINGTON, Del., March 25, 2025----New study results presented at the European Lung Cancer Congress  2025, March 26 to 29, demonstrate the role of AstraZeneca’s TAGRISSO , as monotherapy and as the backbone for novel combinations, across stages and settings of epidermal growth factor receptor-mutated  non-small cell lung cancer . Highlights include:. LAURA Phase III trial of TAGRISSO in unresectable, Stage III EGFRm NSCLC after chemoradiotherapy  .SAVANNAH Phase II trial of TAGRISSO plus savolitinib in advanced EGFRm NSCLC with high levels of MET overexpression and/or amplification following disease progression on 1st-line TAGRISSO (#2O).FLAURA2 Phase III trial of TAGRISSO plus chemotherapy as 1st-line treatment for advanced EGFRm NSCLC .Professor Virginia Harrison, EGFR Positive UK, said: \"For people undergoin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/study-results-reinforce-tagrisso-osimertinib-230200995.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0889565916.HKD","BK4097","BK4007","BK4213","LU1829250122.USD","BK4568","BK4588","LU0320765992.SGD","BK4166","BK4144","ORR","BK4080","BK4124","QD","LU2462157665.USD","OS","LU2417539215.USD","BK4563","LU2456880835.USD","EMM","BK4211","BK4503","LU0109394709.USD","PFS","LU2236285917.USD","CRT","BK4585","TEN","BK4231","BK4195","ADC","AZN"],"gpt_icon":1},{"id":"2522073059","title":"Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2522073059","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522073059?lang=en_us&edition=fundamental","pubTime":"2025-03-25 20:30","pubTimestamp":1742905800,"startTime":"0","endTime":"0","summary":"- U.S. Food and Drug Administration states that data from the ongoing OnPrime/GOG-3076 Phase 3 registrational trial could potentially support traditional approval -. Currently, Olvi-Vec is being evaluated in the OnPrime/GOG-3076 Phase 3 registrational trial in the United States, with the primary endpoint of progression free survival . The purpose of the FDA meeting was to discuss the FDA’s expectations with respect to the requirements necessary for the granting of traditional approval of Olvi-Vec.“We appreciate the feedback from the FDA regarding our clinical strategy for OnPrime/GOG-3076 and the plan for submission of an eventual marketing application, which could avoid the need for conducting a separate confirmatory study if the clinically meaningful PFS advantage is demonstrated,” stated Thomas Zindrick, President and CEO. “The FDA’s guidance regarding their expectations for the ongoing trial represents a significant milestone as we look forward to reporting topline safety and effic","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/genelux-announces-alignment-fda-key-123000034.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4097","GNLX","OS"],"gpt_icon":0},{"id":"2521747447","title":"IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2521747447","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521747447?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:00","pubTimestamp":1742817600,"startTime":"0","endTime":"0","summary":"First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer Initiation of trial sites underway for ground-breaking Phase 3 pivo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/24/3047774/0/en/IMUNON-Finalizes-Phase-3-Study-Design-with-FDA-for-IMNN-001-in-Newly-Diagnosed-Advanced-Ovarian-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMC","IE00B66KJ199.SGD","IE00B1BXHZ80.USD","ITT","LU0971096721.USD","LU0882574139.USD","LU0267386448.USD","BK4161","BK4139","LU1363072403.SGD","IE00BKVL7J92.USD","IMNN","IE0031619046.USD","AEIS","IE00B7SZL793.SGD","IE00BZ1G4Q59.USD","BK4157","LU0053671581.USD","IE00BHPRN162.USD","LU0170899867.USD","LU0054578231.USD","IE00B19Z4B17.USD","BK4006","BK4097","LU0149725797.USD","OS"],"gpt_icon":0},{"id":"2521400452","title":"OS Therapies to Attend The Jones Healthcare and Technology Innovation Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2521400452","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521400452?lang=en_us&edition=fundamental","pubTime":"2025-03-21 19:40","pubTimestamp":1742557200,"startTime":"0","endTime":"0","summary":"NEW YORK, March 21, 2025----OS Therapies  , a clinical-stage immunotherapy and Antibody Drug Conjugate  biopharmaceutical company, today announced that Paul Romness, CEO, and Gerald Commissiong, CBO will be accepting meetings with registered investors at The Jones Healthcare and Technology Innovation Conference. The conference is being held on April 8-9, 2025 at the Venetian Resort in Las Vegas. The Company’s participation aligns with its prioritization of advancements in healthcare and technology while connecting with other investors.Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as \"anticipate,\" \"expect,\" \"intend,\" \"may,\" \"will,\" \"should\" or other comparable terms involve risks and uncertainties because they rela","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/os-therapies-attend-jones-healthcare-114000511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","BK4137","BK4231","OS","BK4080","OSTX","BK4139","HCSG","ADC"],"gpt_icon":0},{"id":"2521406545","title":"HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2521406545","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521406545?lang=en_us&edition=fundamental","pubTime":"2025-03-21 18:00","pubTimestamp":1742551200,"startTime":"0","endTime":"0","summary":"— First and only EZH2 inhibitor approved by the NMPA—。— HUTCHMED’s fourth product, and its first approval in hematological malignancies—。“This approval represents a significant advancement in the management of this challenging disease. The majority of FL patients experience multiple relapses over their lifetime, posing substantial treatment difficulties and often leading to poor outcomes,” said Dr Junning Cao of Fudan University Cancer Center and the lead principal investigator of the bridging study. “TAZVERIK has demonstrated promising efficacy in patients harboring EZH2 mutation in clinical trials. We are eager to provide this transformational epigenetic therapy to patients in China who have long sought new effective treatment options.”TAZVERIK is a first-in-class methyltransferase inhibitor of EZH2 developed by Epizyme. It is approved by the US Food and Drug Administration  for the treatment of certain patients with R/R F","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hutchmed-announces-nmpa-conditional-approval-100000807.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","HCM","OS","BK4195","BK4531","BK4211","BK4097","BK4007","PFS","BK4588"],"gpt_icon":0},{"id":"2521151496","title":"Press Release: SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2521151496","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521151496?lang=en_us&edition=fundamental","pubTime":"2025-03-21 04:05","pubTimestamp":1742501100,"startTime":"0","endTime":"0","summary":"-- Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S  in Acute Myeloid Leukemia  with Next and Final Analysis Planned Upon Reaching 80 Events, Anticipated in 2025 --. -- Reported Positive Overall Survival and Overall Response Rate Data from the Ongoing Phase 2 Trial of SLS009  in r/r AML -- Full Data and FDA Regulatory Path Feedback Expected in 1H 2025 --. Announced Positive Outcome of Interim Analysis for Phase 3 REGAL Trial of GPS in AML: The interim futility, efficacy, and safety analysis was designed to assess whether the therap","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4107","LU2355687059.USD","PR","INN","BK4533","BK4022","BK4213","BK4585","BK4161","BK4181","LU0985320562.USD","BK4202","R","ORR","BK4097","LU1571399168.USD","NCI","BK4183","ODD","BK4109","LU1699723380.USD","BK4232","SLS","BK4218","BK4588","BK4139","ASH","OS","CR","ALL","LU2463526074.USD"],"gpt_icon":0},{"id":"2520413955","title":"OneStream Initiated at Overweight by Stephens & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2520413955","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520413955?lang=en_us&edition=fundamental","pubTime":"2025-03-19 22:02","pubTimestamp":1742392920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 19, 2025 10:02 ET (14:02 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS"],"gpt_icon":0},{"id":"2520937371","title":"Onestream, Inc. Class A (OS) Has a New Rating from Stephens","url":"https://stock-news.laohu8.com/highlight/detail?id=2520937371","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520937371?lang=en_us&edition=fundamental","pubTime":"2025-03-19 04:36","pubTimestamp":1742330163,"startTime":"0","endTime":"0","summary":"Onestream, Inc. Class A (OS – Research Report) received a Buy rating and a $27.00 price target from Stephens analyst Brett Huff today. The company’...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/onestream-inc-class-a-os-has-a-new-rating-from-stephens?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/onestream-inc-class-a-os-has-a-new-rating-from-stephens?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OS"],"gpt_icon":0},{"id":"2520937569","title":"OneStream initiated with an Overweight at Stephens","url":"https://stock-news.laohu8.com/highlight/detail?id=2520937569","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520937569?lang=en_us&edition=fundamental","pubTime":"2025-03-19 04:25","pubTimestamp":1742329530,"startTime":"0","endTime":"0","summary":"Stephens analyst Brett Huff initiated coverage of OneStream (OS) with an Overweight rating and $27 price target The company has high potential to b...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/onestream-initiated-with-an-overweight-at-stephens?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/onestream-initiated-with-an-overweight-at-stephens?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OS","BK4097"],"gpt_icon":0},{"id":"2520931134","title":"Press Release: OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2520931134","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520931134?lang=en_us&edition=fundamental","pubTime":"2025-03-19 04:05","pubTimestamp":1742328300,"startTime":"0","endTime":"0","summary":"Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today. OmniAb, Inc.  today reported financial results for the three and 12 months ended December 31, 2024, and provided operating and partner program updates.\"2024 was a remarkable year featuring double-digit percentage growth in the number of both active partners and programs. Clinical-stage programs advanced well, and we launched new technologies and enhancements that strengthened our platform and expanded our reach,\" said Matt Foehr, Chief Executive Officer of OmniAb. \"We exceeded our internal goals for key metrics and continued to build momentum while optimizing the scalability of our business. We believe our commitment to innovation is a significant competitive advantage and creates exciting opportunities for future growth. We remain steadfast in our strategic direction and are excited about the prospects that lie ahead.\". Net loss for the fourth quarter of 2024 was $13.1 million, or $0.12 per share, compared with a net ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","OABI","BK4550","OS","BK4022","TM","BK4121","BK4097","BK4555","BK4211","BK4516","BK4566","BK4604","BK4195","GD","LU0170899867.USD","03160","R","BK4099","BK4187","BK4585","BK4232","BK4588"],"gpt_icon":0},{"id":"2520767842","title":"QNX Announces Free Online Training Courses to Grow and Empower Global Developer Community","url":"https://stock-news.laohu8.com/highlight/detail?id=2520767842","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520767842?lang=en_us&edition=fundamental","pubTime":"2025-03-18 19:56","pubTimestamp":1742298960,"startTime":"0","endTime":"0","summary":"Training now available to all in a move that reinforces QNX's commitment to developer success and industry innovation. WATERLOO, ON / ACCESS Newswire / March 18, 2025 / QNX, a division of BlackBerry Limited  today announced the launch of its free QNX Online Training. Consisting of three foundational courses totaling 40 hours of in-depth instruction, the training covers topics such as real-time programming, developing and debugging, and system profiling and analysis.The initiative underscores QNX's continued efforts to foster a skilled global developer community equipped with the tools necessary for success developing and building embedded products for the QNX Operating System , and complements the recently launched QNX Everywhere initiative, which has opened up the business' high performance foundational software for non-commercial use with a view to advancing embedded systems learning, experimentation and innovation. The courses will be updated with new content and features planned to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/qnx-announces-free-online-training-115600983.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OS","BB","BK4097","EMPW.U","BK4547"],"gpt_icon":0},{"id":"2520443526","title":"Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2520443526","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520443526?lang=en_us&edition=fundamental","pubTime":"2025-03-17 20:50","pubTimestamp":1742215800,"startTime":"0","endTime":"0","summary":"- Median Overall Survival of 18.4 months with Actimab-A + CLAG-M in patients with relapsed or refractory AML who received 1 or 2 lines of prior therapy. - Mutation agnostic potential of Actimab-A demonstrated by high rates of Complete Remissions and Measurable Residual Disease Negativity in patients with high-risk features including TP53 mutations and prior Venetoclax treatment. - Actimab-A + CLAG-M combination yielded deep and clinically meaningful responses with expected and manageable safety profile supporting planned pivotal Phase 2/3 trial. 52% of patients in the Actimab-A +CLAG-M trial had TP53 mutations, 56% had prior allogeneic stem cell transplant and 56% of patients had prior Venetoclax therapy. Actimab-A + CLAG-M produced high rates of measurable residual disease negativity  including 75% across all patients, 83.3% in patients with a TP53 mutation and 100% in patients with prior Venetoclax therapy. Dr. Sameem Abedin, Associate Professor of Medicine at the Medical College of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-announces-publication-actimab-125000660.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-announces-publication-actimab-125000660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","HMA","BK4202","NCI","BK4161","ATNM","MCW","BK4097","BK4535","CR","BK4139","OS","BK4192"],"gpt_icon":0},{"id":"2520522383","title":"INAB: Introducing INB-600, A γδ T Cell Engager Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2520522383","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520522383?lang=en_us&edition=fundamental","pubTime":"2025-03-17 17:31","pubTimestamp":1742203860,"startTime":"0","endTime":"0","summary":"Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc.  reported 2024 financial and operational results on March 14th, 2025. Other corporate achievements since the third quarter report in mid-November include a stakeholder update on glioblastoma multiforme  and acute myeloid leukemia  efforts and presentations at multiple investor and scientific conferences.The most important information shared related to the INB-100 patients. Trial data was updated by about four months from early August 2024 to January 17th, 2025 and were presented at the Transplantation & Cellular Therapy  Meetings in February. All of the acute myeloid leukemia  patients across both original and expansion cohorts remain in complete remission , with a median follow-up of 20.1 months. All of the AML patients achieved one year of both progression free survival  and overall survival .General & administrative expenses were $12.6 million, falling 6.5% from $13.5 million. The decrease was pri","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inab-introducing-inb-600-t-093100072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065731478.USD","BK4539","BK4006","BK4139","IE00B66KJ199.SGD","IE0031619046.USD","INAB","PFS","IE00B19Z4B17.USD","OS","IE00B7SZL793.SGD","CR","BK4097","INB","CRS","BK4211","BK4161","BK4195"],"gpt_icon":0},{"id":"2519313450","title":"ELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2519313450","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519313450?lang=en_us&edition=fundamental","pubTime":"2025-03-15 20:00","pubTimestamp":1742040000,"startTime":"0","endTime":"0","summary":"Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE compared to chemotherapy in folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer . Data presented in a late-breaking oral presentation at the Society of Gynecologic Oncology  Annual Meeting on Women's Cancer in Seattle. \"Ovarian cancer can be devastating, and when cancer cells stop responding to chemotherapy patients may feel hopeless about their journey. The data presented today reinforce the importance of ELAHERE as a transformative therapy for patients with limited options,\" said Svetlana Kobina, MD, PhD, vice president, oncology medical affairs, AbbVie. \"We remain steadfast in our commitment to bring forward innovative therapies that improve the lives of patients with difficult-to-treat cancers.\". In the United States, ovarian cancer is the leading cause of death from gynecological cancers.3 Each year, approximately 20,000 women","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/elahere-mirvetuximab-soravtansine-gynx-shows-120000918.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/elahere-mirvetuximab-soravtansine-gynx-shows-120000918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OS","BK4585","LU1037948897.HKD","LU2237443978.SGD","ORR","SG9999015952.SGD","LU0320765646.SGD","LU1983299246.USD","IE00BVYPNV92.GBP","LU0708994859.HKD","BK4195","PFS","IE0002141913.USD","LU1244550494.USD","LU1267930573.SGD","PROC","LU0820561818.USD","LU1244550577.SGD","LU1162221912.USD","LU1037948541.HKD","LU0965508806.USD","LU1291159041.SGD","LU1430594728.SGD","LU2237443895.HKD","LU0545039389.USD","LU0170899867.USD","SG9999015986.USD","ADC","LU1934455277.USD","LU1989771016.USD","LU0795875086.SGD","IE00BJJMRZ35.SGD","ABBV","LU1732799900.SGD","LU1989772840.SGD","LU2089283258.USD","LU1244550221.USD","LU0417517546.SGD","LU2112291526.USD","LU1496350502.SGD","BK4533","BK4581","LU2089984988.USD","LU2237443465.HKD","IE00B4R5TH58.HKD","LU0738911758.USD","BK4550","BK4080","LU1003077747.HKD","LU0985320562.USD"],"gpt_icon":0},{"id":"2519838093","title":"OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2519838093","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519838093?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:40","pubTimestamp":1741866000,"startTime":"0","endTime":"0","summary":"NEW YORK, March 13, 2025----OS Therapies, Inc. , a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has been awarded a presentation slot at the MIB Agents Factor Osteosarcoma Conference to be held June 26-28, 2025 in Salt Lake City, Utah. Key data will be presented from the Company’s Phase 2b clinical trial of OST-HER2 in the prevention of recurrent, fully resected, lung metastatic osteosarcoma. This data will be compared with a newly created regulatorily compliant synthetic control group comprised of case matched controls that will be used for the Company’s US Food & Drug Administration  OST-HER2 Biologics License Application  submission. Equivalent submissions with international regulatory authorities will be made in order to gain commercial marketing authorization. MIB Agents FACTOR is the most important annual osteosarcoma conference bringing together the leading osteosarcoma researchers, clini","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/os-therapies-awarded-ost-her2-114000281.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4148","BK4231","BK4080","DC","OS","BK4097","BK4017","OSTX","ADC","OST","BK4139"],"gpt_icon":0},{"id":"2518418748","title":"OS Therapies Schedules United Kingdom’s Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2518418748","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518418748?lang=en_us&edition=fundamental","pubTime":"2025-03-11 19:40","pubTimestamp":1741693200,"startTime":"0","endTime":"0","summary":"NEW YORK, March 11, 2025----OS Therapies, Inc. , a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has scheduled a Scientific Advice Meeting  in the third quarter of 2025 to discuss the Innovative Licensing and Access Pathway  with the United Kingdom’s  Medicines and Healthcare products Regulatory Agency  for OST-HER2, its immunotherapy candidate for the prevention of recurrence of metastases in osteosarcoma. The Company released positive Phase 2b data in January 2025 that demonstrates statistically significant results in the primary endpoint of the study, 12-month event free survival . The meeting with MHRA has been scheduled to position the Company to bring OST-HER2 to market in the UK in 2025.\"Today’s announcement marks the beginning of the regulatory process required to bring our OST-HER2 immunotherapy to market globally,\" stated OS Therapies’ CEO Paul Romness. \"As we prepare for regulatory in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/os-therapies-schedules-united-kingdom-114000512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4231","OSTX","OST","BK4097","HCSG","BK4139","UK","BK4585","OS","SAM","BK4588","BK4137","DC","BK4532","BK4205","BK4158","BK4080","UBCP","BK4017","BK4528","ADC","BK4148","MDCO","BK4211","BK4233"],"gpt_icon":0},{"id":"2518795556","title":"QNX Extends Collaboration with AMD to Boost Performance in Robotic Systems","url":"https://stock-news.laohu8.com/highlight/detail?id=2518795556","media":"ACCESS Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518795556?lang=en_us&edition=fundamental","pubTime":"2025-03-11 16:00","pubTimestamp":1741680000,"startTime":"0","endTime":"0","summary":"New QNX Board Support Packages for AMD Adaptive Compute Devices to Enhance the Next Generation of High-Performance Applications. Building on the collaboration announced in April 2024, QNX and AMD continue to push the boundaries of innovation in embedded systems. The enhanced support for AMD devices underscores QNX's commitment to providing robust solutions for industrial, medical, automotive, and robotic workloads, leveraging the real-time operating system  capabilities of QNX to enable systems to operate within strict timing constraints, crucial for embedded software.QNX's initiative to expand support for AMD devices reflects its commitment to offering developers a range of powerful solutions, fostering a diverse and competitive landscape in embedded systems. QNX uses an abstraction layer of hardware-specific software to facilitate the implementation of QNX software on a chosen development platform. It provides initializations and other architecture and hardware-specific tasks needed ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/qnx-extends-collaboration-amd-boost-080000005.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4605","LU1064131342.USD","IE0009356076.USD","BK4575","LU1242518857.USD","IE0004445239.USD","LU0198837287.USD","BK4612","LU0889565833.HKD","BK4512","LU0056508442.USD","LU0979878070.USD","LU1880398471.USD","LU2264538146.SGD","GFS","OS","LU0823421333.USD","BK4585","LU0082616367.USD","BK4547","BB","LU0719512351.SGD","BK4588","BK4614","BK4141","LU1303367103.USD","LU2458330169.SGD","IE00BMPRXN33.USD","LU2054465674.USD","IE00B5949003.HKD","LU1951200564.SGD","LU2360106780.USD","BK4534","LU1803068979.SGD","BK4554","LU2250418816.HKD","LU0823434583.USD","SDP","AMD","BK4097","LU0127658192.USD","BK4529","BK4543","LU1852331112.SGD","LU0109392836.USD","LU0390134368.USD","LU0823434740.USD","BK4532","LU1316542783.SGD","LU0823421416.USD"],"gpt_icon":1}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-08","symbol":"OS","fiscalQuarterEnding":"2025/03","expectedEps":-0.03,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":0.04},{"market":"US","date":"2025-02-11","symbol":"OS","fiscalQuarterEnding":"2024/12","expectedEps":0.02,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1739250000000,"reportTimeType":"post","actualEps":0.07},{"market":"US","date":"2024-11-07","symbol":"OS","fiscalQuarterEnding":"2024/09","expectedEps":0,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-1.06},{"market":"US","date":"2024-09-03","symbol":"OS","fiscalQuarterEnding":"2024/06","expectedEps":-0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1725336000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.5714,"hold":0.0952,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":21,"updateTime":1748318400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/OS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"OS","date":"2025-06-13","current":-21.083062,"percent":0.688372,"low":-1655.61542,"twenty":-1357.293182,"median":-26.745487,"eighty":-18.76981,"high":-14.493656,"avg":-366.615877,"sd":586.069132,"marketCap":4959958960},"quantilePoints":[{"date":"2024-08-02","current":-402.058638,"twenty":-402.058638,"median":-402.058638,"eighty":-402.058638,"marketCap":4348264172},{"date":"2024-08-09","current":-394.529993,"twenty":-398.004752,"median":-394.602383,"eighty":-391.489578,"marketCap":4266841869},{"date":"2024-08-16","current":-420.156344,"twenty":-402.058638,"median":-395.977809,"eighty":-394.529993,"marketCap":4543990864},{"date":"2024-08-23","current":-418.563746,"twenty":-420.156344,"median":-400.248867,"eighty":-394.674774,"marketCap":4526766915},{"date":"2024-08-30","current":-439.701867,"twenty":-427.829772,"median":-415.668113,"eighty":-395.977809,"marketCap":4755375690},{"date":"2024-09-06","current":-1412.285699,"twenty":-434.093948,"median":-420.156344,"eighty":-395.977809,"marketCap":4652069092},{"date":"2024-09-13","current":-1421.532228,"twenty":-630.517125,"median":-426.381956,"eighty":-397.599363,"marketCap":4682527160},{"date":"2024-09-20","current":-1491.611188,"twenty":-1406.835113,"median":-428.55368,"eighty":-398.352228,"marketCap":4913367253},{"date":"2024-09-27","current":-1641.015636,"twenty":-1479.542034,"median":-435.672004,"eighty":-401.33473,"marketCap":5405505506},{"date":"2024-10-04","current":-1582.129844,"twenty":-1582.616503,"median":-445.348351,"eighty":-408.313205,"marketCap":5211535706},{"date":"2024-10-11","current":-1384.546111,"twenty":-1557.991535,"median":-1361.673117,"eighty":-414.50986,"marketCap":4560694889},{"date":"2024-10-18","current":-1422.505547,"twenty":-1506.405635,"median":-1387.466067,"eighty":-417.984619,"marketCap":4685733272},{"date":"2024-10-25","current":-1513.510863,"twenty":-1501.052381,"median":-1410.582391,"eighty":-419.837824,"marketCap":4985504782},{"date":"2024-10-31","current":-1488.204572,"twenty":-1545.825049,"median":-1419.58559,"eighty":-422.588676,"marketCap":4902145859},{"date":"2024-11-08","current":-29.444986,"twenty":-1544.267739,"median":-1421.532228,"eighty":-422.588676,"marketCap":5359016876},{"date":"2024-11-15","current":-29.547337,"twenty":-1525.190689,"median":-1414.232336,"eighty":-406.749563,"marketCap":5377644907},{"date":"2024-11-22","current":-27.361909,"twenty":-1504.167001,"median":-1405.472467,"eighty":-395.977809,"marketCap":4979894851},{"date":"2024-11-29","current":-26.339693,"twenty":-1496.769778,"median":-1384.546111,"eighty":-392.705744,"marketCap":4793850470},{"date":"2024-12-06","current":-28.33551,"twenty":-1493.655158,"median":-903.058146,"eighty":-29.829328,"marketCap":5157091209},{"date":"2024-12-13","current":-28.454992,"twenty":-1490.248542,"median":-439.701867,"eighty":-28.749622,"marketCap":5178836972},{"date":"2024-12-20","current":-27.223413,"twenty":-1484.895288,"median":-431.521704,"eighty":-28.258307,"marketCap":4954688343},{"date":"2024-12-27","current":-27.048786,"twenty":-1479.834029,"median":-428.191726,"eighty":-28.004145,"marketCap":4922906075},{"date":"2025-01-03","current":-25.973452,"twenty":-1479.444702,"median":-426.381956,"eighty":-27.732022,"marketCap":4727194212},{"date":"2025-01-10","current":-24.227183,"twenty":-1479.444702,"median":-422.183287,"eighty":-27.252823,"marketCap":4409371530},{"date":"2025-01-17","current":-26.460569,"twenty":-1468.54353,"median":-415.668113,"eighty":-26.869269,"marketCap":4815850013},{"date":"2025-01-24","current":-27.894348,"twenty":-1465.818237,"median":-402.058638,"eighty":-26.861301,"marketCap":5076799163},{"date":"2025-01-31","current":-27.407231,"twenty":-1462.314289,"median":-396.991281,"eighty":-26.925021,"marketCap":4988143362},{"date":"2025-02-07","current":-27.09474,"twenty":-1459.102337,"median":-394.674774,"eighty":-26.925021,"marketCap":4931269830},{"date":"2025-02-14","current":-19.646244,"twenty":-1457.642359,"median":-390.041762,"eighty":-26.782239,"marketCap":4247537655},{"date":"2025-02-21","current":-19.437413,"twenty":-1455.695721,"median":-30.305187,"eighty":-26.72172,"marketCap":4202388031},{"date":"2025-02-28","current":-18.385222,"twenty":-1452.094441,"median":-29.520901,"eighty":-26.562732,"marketCap":3974903390},{"date":"2025-03-07","current":-18.486889,"twenty":-1446.059864,"median":-28.777108,"eighty":-26.339693,"marketCap":3996883783},{"date":"2025-03-14","current":-16.449855,"twenty":-1440.122619,"median":-28.454992,"eighty":-26.179328,"marketCap":3556475076},{"date":"2025-03-21","current":-17.921046,"twenty":-1437.981318,"median":-28.198548,"eighty":-25.317223,"marketCap":3874548031},{"date":"2025-03-28","current":-18.76981,"twenty":-1430.38943,"median":-27.986257,"eighty":-24.094834,"marketCap":4058051659},{"date":"2025-04-04","current":-16.296269,"twenty":-1422.116219,"median":-27.889753,"eighty":-20.198845,"marketCap":3523269657},{"date":"2025-04-11","current":-15.87621,"twenty":-1419.974918,"median":-27.820821,"eighty":-19.520945,"marketCap":3432452458},{"date":"2025-04-17","current":-15.802935,"twenty":-1417.346957,"median":-27.682957,"eighty":-19.180725,"marketCap":3416610370},{"date":"2025-04-25","current":-17.317281,"twenty":-1415.400319,"median":-27.425612,"eighty":-18.846182,"marketCap":3744013527},{"date":"2025-05-02","current":-17.960471,"twenty":-1411.604376,"median":-27.370467,"eighty":-18.532156,"marketCap":3883071858},{"date":"2025-05-09","current":-18.233962,"twenty":-1408.19776,"median":-27.329108,"eighty":-18.405555,"marketCap":4289685457},{"date":"2025-05-16","current":-21.240398,"twenty":-1401.871187,"median":-27.223413,"eighty":-18.515128,"marketCap":4996973579},{"date":"2025-05-23","current":-21.307828,"twenty":-1386.882076,"median":-27.071763,"eighty":-18.645114,"marketCap":5012836988},{"date":"2025-05-30","current":-20.970679,"twenty":-1384.546111,"median":-26.979854,"eighty":-18.713226,"marketCap":4933519947},{"date":"2025-06-06","current":-21.779837,"twenty":-1366.053052,"median":-26.837395,"eighty":-18.714534,"marketCap":5123880845},{"date":"2025-06-13","current":-21.083062,"twenty":-1357.293182,"median":-26.745487,"eighty":-18.76981,"marketCap":4959958960}],"updateTime":1750071672882}}}